Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Cash & Current Investments (2009 - 2025)

Grifols' (GIFLF) quarterly Cash & Current Investments came in at $1.2 billion in Q4 2025, down 10.74% on a YoY basis from $1.3 billion in Q4 2024, and down 10.74% quarter-over-quarter from $1.3 billion in Q4 2024.

Analysis

Grifols (GIFLF) Cash & Current Investments (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Cash & Current Investments for 17 consecutive years, with $1.2 billion the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 10.74% year-over-year to $1.2 billion; the trailing twelve-month figure through Dec 2025 stood at $1.2 billion (down 10.74% YoY), and the FY2025 full-year result was $1.1 billion, down 13.37% from the prior year.
  • Cash & Current Investments retreated to $1.2 billion in Q4 2025 per GIFLF's latest filing, from $1.3 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $5.4 billion in Q4 2021 and bottomed at $469.1 million in Q4 2023.
  • Historically, Cash & Current Investments has averaged $1.9 billion across 5 years, with a median of $1.2 billion in 2025.
  • The sharpest annual moves came in 2021 and 2022: Cash & Current Investments jumped 716.79% in 2021, then tumbled 80.9% in 2022.
  • Over 5 years, Cash & Current Investments stood at $5.4 billion in 2021, then sank by 80.9% to $1.0 billion in 2022, then plunged by 54.34% to $469.1 million in 2023, then surged by 177.45% to $1.3 billion in 2024, then slipped by 10.74% to $1.2 billion in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods registered $1.2 billion, $1.3 billion, and $469.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 13.99 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 3.18 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 7.85 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 7.99 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 5.18 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 5.14 Bn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 3.31 Bn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 1.29 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn -
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn 1.16 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1.16 Bn
Dec 31, 2024 1.30 Bn
Dec 31, 2023 469.11 Mn
Dec 31, 2022 1.03 Bn
Dec 31, 2021 5.38 Bn
Dec 31, 2020 658.63 Mn
Sep 30, 2020 1.22 Bn
Mar 31, 2020 718.37 Mn
Dec 31, 2019 799.77 Mn
Sep 30, 2019 884.51 Mn
Mar 31, 2019 858.09 Mn
Dec 31, 2018 1.30 Bn
Sep 30, 2018 736.73 Mn
Jun 30, 2018 843.10 Mn
Mar 31, 2018 1.05 Bn
Dec 31, 2017 1.06 Bn
Jun 30, 2017 847.46 Mn
Dec 31, 2016 969.15 Mn
Sep 30, 2016 1.01 Bn
Jun 30, 2016 920.90 Mn